Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of PN20 for chemotherapy-induced thrombocytopenia
CTR20253698Phase 2Active
- Sponsor
- Chongqing Paijin Biotechnology
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of PJ004 in chemotherapy-induced thrombocytopenia (CIT), sponsored by Chongqing Paijin Biotechnology. Started Dec 2025; status: active.
02
Drugs
PJ004
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on CTR20253698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253698.